Summary: In the “Behind the Paper” section of Nature Portfolio’s research blog, Jennifer Mitchell, Ph.D., and Allison Coker, Ph.D., illustrate the context in which MAPS’ first Phase 3 trial of MDMA-assisted therapy for PTSD was born, including the history of MDMA, including its stigmatization, and MAPS’ years-long fundraising efforts that supported the study’s completion.
As lead author and contributing author of the study that was published yesterday by Nature Medicine, Dr. Mitchell and Dr. Coker ponder “society’s cognitive flexibility” given the increase in evidence-based research surrounding MDMA-assisted therapy: “can we overcome our previous misconceptions and finally evaluate these compounds objectively?”
Originally appearing here.
